Francesco Lo-Coco

Francesco Lo-Coco's AcademicInfluence.com Rankings

Francesco Lo-Coco

Philosophy

#11462

World Rank

#15782

Historical Rank

Logic

#8281

World Rank

#10338

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Francesco Lo-Coco Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Francesco Lo-Coco's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells (2001) (1785)
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. (1993) (690)
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. (2000) (616)
Acute promyelocytic leukemia: from genetics to treatment. (1994) (537)
p53 mutations are associated with histologic transformation of follicular lymphoma. (1993) (389)
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. (1994) (378)
Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Mole (2000) (333)
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. (2005) (319)
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. (1994) (303)
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. (1992) (281)
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. (1996) (265)
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. (1991) (260)
Therapy of molecular relapse in acute promyelocytic leukemia. (1999) (238)
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. (1997) (224)
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. (1999) (218)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. (2009) (207)
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias (1990) (205)
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. (2006) (195)
Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. (1992) (191)
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. (2005) (191)
Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases (1998) (187)
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. (2008) (161)
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. (2000) (157)
Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. (1992) (142)
Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. (2001) (139)
Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). (1997) (131)
ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. (1993) (129)
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. (2005) (125)
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. (1995) (124)
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. (1996) (123)
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. (2002) (123)
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. (2010) (122)
Genetic characterization of HHV‐8/KSHV–positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis (1999) (113)
RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. (1991) (110)
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. (2002) (109)
GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. (2019) (106)
Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. (1997) (105)
Extranodal lymphomas associated with hepatitis C virus infection. (1998) (104)
Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. (1996) (102)
A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. (1995) (101)
Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements (2003) (96)
Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. (1998) (95)
Increase in platelet count in older, poor‐risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all‐trans retinoic acid (2005) (93)
Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. (1991) (91)
Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. (1995) (89)
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. (1994) (88)
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. (1991) (79)
The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia. (2019) (78)
Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. (1992) (75)
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. (2005) (74)
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. (2001) (72)
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. (1997) (69)
Identification of genetic lesions associated with diffuse large-cell lymphoma. (1994) (68)
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. (1997) (66)
Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. (2002) (66)
Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. (1997) (60)
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men. (1999) (59)
Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. (1990) (55)
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‐70‐negative chronic lymphocytic leukemia (2005) (52)
Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. (1997) (49)
High-mobility group A1 proteins are overexpressed in human leukaemias. (2003) (48)
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. (2004) (46)
Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL‐1/AF‐4 positive‐acute lymphoblastic leukaemia (1996) (46)
Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. (2014) (42)
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. (1993) (42)
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. (2018) (41)
The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. (1995) (40)
Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. (1996) (39)
Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. (1998) (39)
Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. (2001) (39)
Frequency of RAS and p53 mutations in acute promyelocytic leukemias. (1993) (39)
Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period. (1994) (39)
Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. (2003) (37)
Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. (1994) (37)
Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients: a clinicopidemiologic variant resembling classic Kaposi's sarcoma. (2002) (36)
Identification of DNA rearrangements at the retinoic acid receptor-alpha (RAR-alpha) locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RAR-alpha second intron. Italian Cooperative Study Group "GIMEMA". (1992) (35)
Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemia. (1993) (34)
Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi's sarcoma and multicentric Castleman's disease. (1999) (33)
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. (2006) (32)
Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults (2014) (32)
BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. (1995) (30)
Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines (2015) (29)
Apoptosis and immaturity in acute myeloid leukemia (2005) (29)
The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. (1997) (28)
Primary effusion lymphoma containing human herpesvirus 8 DNA in two AIDS patients with Kaposi's sarcoma. (1998) (27)
The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. (1998) (27)
BCL-6 and the molecular pathogenesis of B-cell lymphoma. (1994) (25)
Immunophenotype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group (Gimema). (1993) (25)
Promyelocytic Sarcoma of the Spine: A Case Report and Review of the Literature (2010) (25)
BCL-6 in diffuse large-cell lymphomas. (1996) (23)
p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. (1995) (21)
Distribution of TP53 mutations among acute leukemias with MLL rearrangements (1996) (21)
Advances in the understanding and management of acute promyelocytic leukemia. (2002) (21)
Current treatment of acute promyelocytic leukemia. (2007) (19)
Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting. (1990) (19)
Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. (1989) (18)
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. (2004) (18)
Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia. (2019) (18)
Immune-deficiency in Hodgkin's disease (HD): a study of patients and healthy relatives in families with multiple cases. (1988) (18)
Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia (1997) (17)
Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells (2015) (17)
AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. (2002) (17)
CD5 negative lymphocytosis mimicking typical B-chronic lymphocytic leukaemia. Description of 26 cases. (1993) (17)
Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. (1990) (17)
A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review (2019) (16)
Expression of GATA-1 mRNA in human myeloid leukemic cells. (1994) (16)
Occurrence of a Ki-1-positive anaplastic large-cell lymphoma in a patient with Ph' positive chronic myelogenous leukemia successfully treated by alpha-interferon. (1993) (16)
Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. (2019) (16)
Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype. (1991) (15)
The genotype nucleophosmin mutated and FLT3‐ITD negative is characterized by high bax/bcl‐2 ratio and favourable outcome in acute myeloid leukaemia (2010) (15)
Variant t(1;15;17)(q23;q22;q23) in a case of acute promyelocytic leukemia. (1996) (15)
Alterations of the BCL-6 gene in diffuse large-cell lymphoma. (1995) (15)
Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. (2005) (14)
Multigenetic lesions in infant acute leukaemias: correlations with ALL‐1 gene status (1997) (14)
Acute leukemia presenting a variant Ph chromosome with p190 expression, dup 3q and -7, developed after malignant lymphoma treated with alkylating agents and topoisomerase II inhibitors. (1995) (13)
Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements. (1993) (13)
Molecular monitoring of hematologic malignancies: current and future issues. (2002) (13)
”Composite” lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin (1999) (13)
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. (2019) (12)
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia (2018) (12)
Molecular characterization of Ph' + hybrid acute leukemia. (1989) (11)
Analysis of the BCL‐6 gene configuration in diffuse B‐cell non‐Hodgkin's lymphomas and Hodgkin's disease (1995) (10)
FLT3 inhibition as tailored therapy for acute myeloid leukemia. (2003) (10)
Acute lymphoblastic leukemia with the 4;11 translocation exhibiting early T cell features. (1989) (10)
Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. (1994) (9)
Molecular biology to check patients treated for CML. (1989) (9)
Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia. (1999) (9)
Clinical relevance of the PML/RAR-a gene rearrangement in acute promyelocytic leukaemia. (1994) (9)
Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia. (2006) (8)
Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. (2000) (8)
All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature (2016) (7)
Identical utilization of T-cell receptor gene regions in B-lymphoid blast crisis of chronic myeloid leukemia and B-precursor acute lymphoblastic leukemia. (1991) (7)
Immunoglobulin heavy chain and T-cell receptor beta chain gene rearrangements in acute non lymphoid leukemia. (1990) (6)
Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol (2017) (6)
Hybrid phenotypes and lineage promiscuity in acute leukemia. (1991) (6)
Kaposi’s sarcoma following malignant mesothelioma (1999) (6)
Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation. (1990) (5)
Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results. (1993) (5)
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS) (2018) (4)
Absence of HHV-8 DNA sequences in malignant mesothelioma. (1998) (4)
Pregnancy in acute promyelocytic leukaemia after front‐line therapy with arsenic trioxide and all‐trans retinoic acid (2014) (4)
Interferon therapy for Ph1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation. (1991) (4)
MLL tandem duplication in two cases of acute myelocytic leukemia with unbalanced translocations: der(16)t(11;16)(q23;p13) and der(18)t(11;18)(q22;p11.2). (2003) (4)
Herpesvirus 8-negative primary effusion lymphoma associated with hepatitis C virus. (2000) (3)
Molecular diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia. (1991) (3)
Repeated PCR in CML during IFN-alpha therapy. (1994) (3)
Single or multistep origin of hemopoietic tumors: the contribution of clonality studies. (1995) (3)
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia. (2009) (2)
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. (2002) (2)
PCR-detectable transcripts in long-term remission of P190(BCR/ABL)-positive acute lymphoblastic leukemia. (2000) (2)
On the differentiative mode of action of All-trans retinoic acid in acute promyelocytic leukemia. (1995) (1)
Patient‐reported outcomes in acute leukemia: a roadmap for future research (2014) (1)
Terminal deoxynucleotidil transferase (TdT) activity in human leukemia. Quantitative evaluation with enzymatic immunoassay (EIA). (1986) (1)
A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review (2019) (0)
Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia. (1993) (0)
Clonality studies in CML patients treated by IFN and/or autologous bone marrow transplantation. (1994) (0)
Development and overcoming of ATRA resistance in acute promyelocytic leukemia. (1999) (0)
CALLA-negative, TdT- and CD7-positive acute lymphoblastic leukemia: a phenotype associated with poor prognosis. (1987) (0)
Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNA. (2005) (0)
Myeloperoxidase gene expression in non‐infant pro‐B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript (2000) (0)
Cost of Treating Acute Promyelocytic Leukemia (APL) Patients in Italy. (2014) (0)
Guidelines in hematology. (2002) (0)
Polyclonal hemopoiesis in leukemia patients following molecularly documented remission. (1994) (0)
Ontogeny, gene rearrangements and immunophenotype of acute leukaemias. (1989) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Francesco Lo-Coco?

Francesco Lo-Coco is affiliated with the following schools:

Francesco Lo-Coco's Academic­Influence.com Rankings

Why Is Francesco Lo-Coco Influential?

Francesco Lo-Coco's Published Works

Published Works

What Schools Are Affiliated With Francesco Lo-Coco?

Francesco Lo-Coco's AcademicInfluence.com Rankings